Navigation Links
Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Date:1/8/2009

Kidney transplantation to be Quark's second indication with clinical-stage, systemically administered siRNA product candidate

FREMONT, Calif., Jan. 8 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that it has initiated patient dosing in its Phase I/II clinical trial evaluating its systemically administered siRNA drug candidate QPI-1002 (previously referred to as DGFi) for prevention of Delayed Graft Function (DGF) in patients undergoing deceased donor kidney transplantation. DGF represents Quark's second indication being evaluated for the systemically administered dug candidate in human clinical trials. This trial follows two currently enrolling Phase I clinical trials in acute kidney injury (AKI).

The multi-center, two-part Phase I/II clinical trial in DGF is expected to enroll up to 204 adult kidney transplant recipients. The first part of the study is a dose-escalation design to evaluate the safety and tolerability of a single intravenous injection of QPI-1002 in renal transplant patients at high risk to develop DGF. The second part of the study will evaluate safety and potential clinical activity of a selected dose of QPI-1002 in the same patient population. Patients will be enrolled in clinical sites in the United States.

Shai Erlich, Ph.D., Chief Medical Officer of Quark, commented, "The initiation of patient dosing with QPI-1002 is an important milestone for Quark as well as being an innovative approach to offer therapeutic benefit to adult kidney transplant patients at high risk for developing DGF. The siRNA drug candidate is based on the proprietary concept of Quark and reflects Quark's success in developing products originating from conceptually novel internal developments. These accomplishments further validate Quark's ability to advance innovative product candida
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
6. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
7. Quark Pharmaceuticals Appoints New Chief Medical Officer
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)...  Following US and European approvals of Elekta,s ... Drug Administration (CFDA) has cleared the radiation therapy system ... According to the International Agency for Research on Cancer, ... every year in China 1 ... liver and esophageal cancers 2 . Versa HD is ...
(Date:9/29/2014)... Research and Markets has announced the ... and Forecasts, 2012-2018" report to their offering. ... billion by 2016. The North American segment accounts for nearly ... Europe claims approximately 30% (2018). Asia-Pacific ... of 11.4% driving a market value of US$728 million by ...
(Date:9/29/2014)... 29, 2014  On Oct. 2, some 24,000 Lilly ... company,s seventh Global Day of Service. Building on Lilly,s ... together in a single, coordinated effort to improve the ... "I,m so proud of this tradition, and of ... to strengthening the communities around the world where we ...
Breaking Medicine Technology:Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 2Chinese clinics and cancer patients to benefit from Elekta's Versa HD radiation therapy system 3Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 2Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 3Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 4Global Cardiac Pacemakers - Trends, Estimates and Forecasts to 2018 5Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 2Lilly's seventh Global Day of Service rallies 24,000 employees in nearly 60 countries 3
... affiliated medical groups -- Sharp Rees-Stealy and Sharp Community ... possible designation for quality care given by the California ... 2011 Standards of Excellence program. CAPG is one of ... groups. "We are grateful to be recognized ...
... Calif., Sept. 20, 2011 CMC Biologics and ... companies have entered into a long-term commercial supply ... intravenous recombinant factor IX (rFIX) product, for the ... hemophilia B. Under the terms of the agreement, ...
Cached Medicine Technology:Sharp HealthCare Medical Groups Recognized for "Elite" Care 2Sharp HealthCare Medical Groups Recognized for "Elite" Care 3CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 2CMC Biologics Enters Commercial Supply Agreement with Inspiration Biopharmaceuticals for IB1001 3
(Date:9/30/2014)... AutoTex PINK proudly offers pink ... in support of breast cancer awareness and research in ... non-profits to “go pink” -- supporting walks, runs and ... a woman-owned company that is among the nation’s leading ... partnering with their customers to raise breast cancer awareness ...
(Date:9/30/2014)... DC (PRWEB) September 30, ... **MEDIA ADVISORY** , From:        Hope ... Barnwell, 910.554.1505, abarnwell(at)hopeforthewarriors(dot)org ... Hope® Celebration , Date:        Thursday, ... Address:    The Army and Navy ...
(Date:9/30/2014)... Every New Year begins with a Resolution that will soon be ... effort, however most are out of mind in 30. Why? , ... of "spend more time with children", try something easy to do ... a reminder, daily life gets in the way and efforts to ... Goals out of sight equals goals out of mind. , ...
(Date:9/30/2014)... Miraca Life Sciences (MLS), the nation’s largest ... at the annual meeting of the American College of ... Scientific Meeting and Postgraduate Course in Philadelphia, Pa., on ... Life Sciences will be at booth 711 to share ... The research posters for ACG provide a wide range ...
(Date:9/30/2014)... Youth Town’s annual BBQ/Music Festival will take place ... at the Youth Town campus (3641 Youth Town Road ... festival, which will offer music, food and games. Admission ... show, arts and crafts fair, music, championship barbeque competition, ... McQueen and Mater from the hit Disney movie “Cars” ...
Breaking Medicine News(10 mins):Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 2Health News:Change Your Blades … Change A Life! AutoTex PINK Wiper Blades Are Helping Wipe Out Breast Cancer 3Health News:Hope For The Warriors' Got Heart, Give Hope Celebration Media Advisory 2Health News:Miraca Life Sciences Research Institute to Present Eight GI Pathology Research Studies at Annual Meeting of American College of Gastroenterologists 2
... with advanced prostate cancer suggest they can be good ... study found a 20-year survival rate for 80 percent ... beyond the prostate, known as cT3 prostate cancer, and ... prostate gland. Previously, patients found to have cT3 prostate ...
... using cells from the interior of the nose could help ... treatable stages, according to a study conducted by researchers ... ATS 2011 International Conference. "Our data suggests that evaluating ... surface of the nose may serve as a non-invasive approach ...
... As Americans head toward attics, roofs and yards to freshen ... cleaning can lead to a spring visit to the hospital. ... on a stepladder, and more than 41,000 suffered injuries while ... Product Safety Commission. In addition, over 127,000 were injured while ...
... databases in 2010, researchers looked at the distribution ... health departments or national organizations (such as The ... Association/American Stroke Association). They found that 24 percent ... Notably, in the eight states that have ...
... --,Caring for a loved one who is ill is always ... dementia may face an increased risk for cognitive problem or ... the May issue of the Journal of the American ... their own mental health and ability to care for their ...
... , FRIDAY, May 13 (HealthDay News) -- Chest compressions ... of chest injury, according to new research. The ... Journal of Manipulative and Physiological Therapeutics , measured and ... extremely rigorous and found all to be well under the ...
Cached Medicine News:Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 2Health News:Gene expression changes in nasal cells may help identify lung cancer in earliest stages 3Health News:Spring Cleaning Lands Many Americans in Hot Water 2Health News:Older Caregivers at Greater Risk for Cognitive Decline 2Health News:Chiropractic Spinal Manipulation Won't Cause Chest Injuries, Study Contends 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: